Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash & Equivalents (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Cash & Equivalents data on record, last reported at $83.4 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 44.41% year-over-year to $83.4 million; the TTM value through Sep 2025 reached $83.4 million, down 44.41%, while the annual FY2024 figure was $128.0 million, 33.15% down from the prior year.
  • Cash & Equivalents reached $83.4 million in Q3 2025 per STOK's latest filing, down from $101.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $274.8 million in Q1 2025 and bottomed at $67.8 million in Q2 2022.
  • Average Cash & Equivalents over 4 years is $150.2 million, with a median of $150.0 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 183.47% in 2023, then crashed 47.55% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $113.6 million in 2022, then soared by 68.59% to $191.4 million in 2023, then plummeted by 33.15% to $128.0 million in 2024, then crashed by 34.84% to $83.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $83.4 million in Q3 2025, $101.5 million in Q2 2025, and $274.8 million in Q1 2025.